New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

November 2014


PharmSource Lead Sheet Global Activity Report:

Lead Type October 2014 2014 YTD
Early Development 103 822
Late Development 86 958
Biologic 87 791
Small Molecule 211 2006
Parenteral 102 909
Oral 72 828
New Financings 97 901
Total Drug Leads 360 3546
Total Device &
Diagnostic Leads
130 1482

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

ABIVAX plans to begin a Phase I trial in 2015 with ABX318, an HPV vaccine that contains a novel fusion antigen based on the E7 antigens from high-risk HPV 16, 18, 31, 45 and 52. Learn more.

CDMO and CRO Outlook: Robust Market Conditions Augur Growth,
More M&A Activity Ahead

When analyzing prospects for the contract development services market, PharmSource divides the bio/pharmaceutical industry into two broad segments: companies that generate sufficient revenues to fund their R&D activities internally, and companies that must rely on external financing, including venture capital and public offerings… More about this Trend Report

Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing

• Analysis of recent trends in capital spending by bio/pharmaceutical companies and assesses the implications for the CMO industry

• Tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic bio/pharma companies

More about this Trend Report

Clinical Developments in the Prevention and Treatment of Ebola Virus

by Judy Nanthavong, Senior Research Analyst

New opportunities to play a supporting business role may be uncovered by following drug products in clinical development and associated bio/pharma company fundings. Recent activity of this nature to prevent and treat the Ebola virus is one such example.

There are not yet any FDA-approved treatments for the Ebola virus, however NIAID has initiated blinded Phase I clinical trials with the VSV-ZEBOV vaccine candidate at three different dosage strengths, in two intramuscular injections, administered 28-days apart. In addition to these efforts, some other bio/pharmaceutical companies have received funding to support the development of new antiviral treatments and vaccines to prevent/treat Ebola…

Click here to read the full report and view the current Ebola pipeline overview.

Our website isn’t the only thing new at PharmSource

We’ve re-engineered our website to showcase PharmSource’s deep content on bio/pharma outsourcing. You’ll find great new information the next time you visit

Expert content that’s free to all: bookmark the site and visit often to see our latest thinking on the contract services industry.

Introducing the PharmSource Blog: get the inside track on Jim Miller’s sourcing insights and our staff’s current focus. Join the conversation or leave a comment.

Industry insights, opinions and intelligence: an entire website devoted to expert information you can put to work in your own business efforts.

We hope you’ll visit the new today.

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).